prikaz prve stranice dokumenta Treatment-Related Risk Factors for Adverse Outcomes of COVID-19 in Patients Treated for Lymphoid Malignancies in the Pre-Omicron Era—A Study of KroHem, the Croatian Group for Hematologic Diseases
  Preuzmi
PDF 2.8 MB
Znanstveni rad - Izvorni znanstveni rad
Treatment-Related Risk Factors for Adverse Outcomes of COVID-19 in Patients Treated for Lymphoid Malignancies in the Pre-Omicron Era—A Study of KroHem, the Croatian Group for Hematologic Diseases
Biomedicines, 12 (2024), 2; 331. https://doi.org/10.3390/biomedicines12020331
Aurer, Igor; Jakšić, Ozren; Bašić-Kinda, Sandra; Mrđenović, Stefan; Ostojić-Kolonić, Slobodanka; Lozić, Dominik; Holik, Hrvoje; Novaković-Coha, Sabina; Berneš, Petra; Krečak, Ivan; Morić-Perić, Martina; Narančić, Marino; Mitrović, Zdravko; Valković, Toni

Citirajte ovaj rad

Aurer, I., Jakšić, O., Bašić Kinda, S., Mrđenović, S., Ostojić Kolonić, S., Lozić, D. ... Valković, T. (2024). Treatment-Related Risk Factors for Adverse Outcomes of COVID-19 in Patients Treated for Lymphoid Malignancies in the Pre-Omicron Era—A Study of KroHem, the Croatian Group for Hematologic Diseases. Biomedicines, 12. (2). doi: 10.3390/biomedicines12020331

Aurer, Igor, et al. "Treatment-Related Risk Factors for Adverse Outcomes of COVID-19 in Patients Treated for Lymphoid Malignancies in the Pre-Omicron Era—A Study of KroHem, the Croatian Group for Hematologic Diseases." Biomedicines, vol. 12, br. 2, 2024. https://doi.org/10.3390/biomedicines12020331

Aurer, Igor, Ozren Jakšić, Sandra Bašić Kinda, Stefan Mrđenović, Slobodanka Ostojić Kolonić, Dominik Lozić, Hrvoje Holik, et al. "Treatment-Related Risk Factors for Adverse Outcomes of COVID-19 in Patients Treated for Lymphoid Malignancies in the Pre-Omicron Era—A Study of KroHem, the Croatian Group for Hematologic Diseases." Biomedicines 12, br. 2 (2024). https://doi.org/10.3390/biomedicines12020331

Aurer, I., et al. (2024) 'Treatment-Related Risk Factors for Adverse Outcomes of COVID-19 in Patients Treated for Lymphoid Malignancies in the Pre-Omicron Era—A Study of KroHem, the Croatian Group for Hematologic Diseases', Biomedicines, 12(2). doi: 10.3390/biomedicines12020331

Aurer I, Jakšić O, Bašić Kinda S, Mrđenović S, Ostojić Kolonić S, Lozić D, i sur.. Treatment-Related Risk Factors for Adverse Outcomes of COVID-19 in Patients Treated for Lymphoid Malignancies in the Pre-Omicron Era—A Study of KroHem, the Croatian Group for Hematologic Diseases. Biomedicines [Internet]. 31.01.2024. [pristupljeno 19.12.2024.];12(2). doi: 10.3390/biomedicines12020331

I. Aurer, et al., "Treatment-Related Risk Factors for Adverse Outcomes of COVID-19 in Patients Treated for Lymphoid Malignancies in the Pre-Omicron Era—A Study of KroHem, the Croatian Group for Hematologic Diseases", Biomedicines, vol. 12, br. 2, Siječanj 2024. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:105:699245. [Citirano: 19.12.2024.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:105:699245
Prijavite se u repozitorij kako biste mogli spremiti objekt u svoju listu.
Podaci o radu
Naslov (engleski)Treatment-Related Risk Factors for Adverse Outcomes of COVID-19 in Patients Treated for Lymphoid Malignancies in the Pre-Omicron Era—A Study of KroHem, the Croatian Group for Hematologic Diseases
AutorIgor Aurer
AutorOzren Jakšić
AutorSandra Bašić-Kinda
AutorStefan Mrđenović
AutorSlobodanka Ostojić-Kolonić
AutorDominik Lozić
AutorHrvoje Holik
AutorSabina Novaković-Coha
AutorPetra Berneš
AutorIvan Krečak
AutorMartina Morić-Perić
AutorMarino Narančić
AutorZdravko Mitrović
AutorToni Valković
Autorova ustanovaSveučilište u Zagrebu
Medicinski fakultet
(KATEDRA ZA INTERNU MEDICINU)
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Kliničke medicinske znanosti
Interna medicina
Sažetak (engleski)
Patients with lymphoid malignancies are at increased risk of death or prolonged infection due to COVID-19. Data on the influence of different antineoplastic treatment modalities on outcomes are conflicting. Anti-CD20 monoclonal antibodies increase the risk of prolonged infection. It is unclear whether this risk is affected by the choice of the antibody (rituximab vs. obinutuzumab). To elucidate the role of antineoplastic therapy on COVID-19 outcomes, KroHem collected data on patients with lymphoid malignancies diagnosed with COVID-19 between October 2020 and April 2021. A total of 314 patients were identified, 75 untreated, 61 off treatment and 178 on treatment. The mortality rate in untreated and off-treatment patients was 15% and 16%; 9% and 10% had prolonged infection. In the on-treatment group, 3% were still prolonged positive at time of data collection, 62% recovered and 35% died; 42% had prolonged infection. Disease type, use of anti-CD20 monoclonal antibodies, prior autologous stem-cell transplantation (ASCT) and line of treatment did not significantly affect mortality. Mortality was higher in older patients (p = 0.0078) and those treated with purine analogues (p = 0.012). Prolonged COVID-19 was significantly more frequent in patients treated with anti-CD20 monoclonal antibodies (p = 0.012), especially obinutuzumab, and purine analogues (p = 0.012). Age, prior ASCT and treatment line did not significantly affect risk of prolonged infection. These data suggest that increased age and use of purine analogues are main risk factors for increased mortality of COVID-19 in patients with lymphoid malignancies. Obinutuzumab further increases the risk of prolonged disease, but not of death, in comparison to rituximab. Epidemiological considerations should be taken into account when choosing the appropriate antineoplastic therapy for patients with lymphoid malignancies.
Ključne riječi (engleski)
Jezikengleski
Vrsta publikacijeZnanstveni rad - Izvorni znanstveni rad
Status objaveObjavljen
Vrsta recenzijeRecenziran
Verzija publikacijeObjavljena verzija rada (izdavačev PDF)
Naslov časopisaBiomedicines
Brojčani podacivol. 12, br. 2, 331
e-ISSN2227-9059
DOIhttps://doi.org/10.3390/biomedicines12020331
URN:NBNurn:nbn:hr:105:699245
Datum objave publikacije2024-01-31
URL dokumentahttps://www.mdpi.com/2227-9059/12/2/331
Vrsta resursaTekst
Prava pristupaOtvoreni pristup
Uvjeti korištenjaIkona licence Imenovanje 4.0 međunarodna (CC BY 4.0)
Datum i vrijeme pohrane2024-11-13 14:58:29